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CHAPTER ONE 
LITERATURE REVIEW 
Statement of the Problem 
Parkinson’s disease (PD) is the second most prevalent neurodegenerative disorder 
globally. PD patients exhibit multiple debilitating symptoms, notably movement-related 
disorders, as well as cognitive and behavioral problems[1]. It affects 1-2% of the 
population over the age of 50 with a current estimation of 1.5 million in the United States 
alone[2]. The pathological hallmark of PD is the loss of dopaminergic neurons of the 
substantia nigra pars compacta (SNpc). The loss of these neurons underlies the movement 
related disorders in PD patients. Current treatments of PD do not affect the pathological 
mechanisms in which the disease progression occurs [3, 4].  
Lewy bodies and Lewy neurites (LB/LN) are found in the cells of the substantia 
nigra pars compacta. They are considered a histological hallmark of Parkinson’s disease. 
LB/LN are somewhat spherical structures that displace other cellular components (Fig 1). 
Mutated/aggregated forms of the protein Α-syn have been identified as the major protein 
component of LB/LN formed during PD progression[5]. Numerous studies have shown 
that the duplication, triplication and/or mutations of the α-syn gene are the cause of PD 
development and progression in affected individuals [6-9]. These pathological α-syn 
proteins are able to transfer between cells thus spreading their pathology [10]. The 
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pathway in which these α-syn entered these uninfected cells has been unknown, 
until recently. 
 
 
 
Figure 1. Lewy Bodies are a histological hallmark of Parkinson’s Disease.  Lewy 
bodies are spherical composites of mutated and aggregated forms of the protein α-syn. 
They are found in the substania nigra of individuals who suffer from Parkinson’s Disease. 
This figure is an H & E stain from Ella Bossy-Wetzel (2004) [11]. 
 
Additionally, evidence of mitochondrial dysfunction, increases in the production 
of Reactive Oxygen Species (ROS) and decreases in antioxidant production in PD 
patients and PD animal models have also been clearly documented[12-14]. These finding 
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are correlative since mitochondrial dysfunction has been shown to increase ROS 
production[15]. This increase in ROS in patients with PD is believed to be the underlying 
cause of cell dysfunction and cell death. It has been theorized that the presence of 
pathological forms of α-syn are the cause of these physiological signs of mitochondrial 
dysfunction. Therefore, it was pertinent to identify the pathway in which the pathological 
forms of α-syn entered uninfected cells. 
To determine if pathological α-syn enters uninfected cells through endocytosis, 
the cytosolic protein Gal3 was utilized to visualize the colocalization of α-syn with 
ruptured vesicles in vitro [16](Fig 2). Gal3 is a lectin protein present diffusely throughout 
the cell cytosol that binds the β-galactoside sugars on the inner leaflet of the lysosome 
[17]. Once the pathological α-syn ruptures the lysosomal vesicle, the β-Galactoside 
sugars are exposed to the cytosol allowing the cytosolic Gal3 to bind and aggregate on 
the inner leaflet. Although pathological α-syn has been shown to rupture lysosomes in 
vitro, its ability to rupture lysosomes or endosomes has yet to be demonstrated in vivo. 
We hypothesize that the utilization of Gal3 as a marker of ruptured vesicles in vivo will 
allow us to determine whether pathological forms of α-syn cause the rupture of vesicles 
in vivo.  
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Figure 2. Cytosolic Galectin 3 can be utilized as a marker of ruptured vesicles in 
vitro. Gal3 has a low affinity for the B-galactosides on the inner leaflet of endosomes. 
When the membrane of the endosome ruptures the cytosolic Gal3 can enter the vesicle 
and bind the B-galactosides on the inner leaflet. Therefore, when α-syn  ruptures the 
vesicle membrane the colocalization of the Gal3 and α-syn  can be observed. This figure 
was provided by D. Freeman [16].  
   
The Epidemiology of Parkinson’s Disease. 
PD poses an increasingly large burden both socially and economically on many 
societies with aging populations. PD pathogenesis causes the development of crippling 
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symptoms in affected individuals. The development of the classic motor control related 
signs of PD is the primary base for diagnosis. Unfortunately, development of these signs 
indicates the disease has caused significant damage to the dopaminergic neurons of the 
SNpc[4]. There is currently no approved treatment for PD that targets a component in the 
etiology of PD. Genetic risk factors for PD development include both inheritable and 
sporadic gene mutations.  These mutations have been the focus of a majority of research 
pertaining to PD[18]. 
PD is clearly an age related disease. Epidemiological studies have shown a rare 
occurrence of PD before 50 years. The prevalence of the disease increases significantly 
with age. PD was diagnosed in nearly 4% of the highest age group (80yrs+)[19]. The 
annual economic impact of PD in the United States is estimated at $10.8 billion. The 
annual direct medical cost to an affected individual is between $10,043 and $12,491. 
These are more than double the annual amount spent on patients without the disease. 
Nursing home care accounts for a large portion of the patients total direct medical cost. 
The development of motor control dysfunctions caused by PD forces many patients to 
enter nursing home care[20, 21]. 
PD causes patients to develop multiple behavioral and motor control 
dysfunctions. Behavioral problems include the development of depression, anxiety, fear 
or isolation. Dementia develops in about 25-40% of patients with PD[22]. Dementia 
seems largely responsible for the reduced life expectancy of patients with PD. Motor 
control dysfunctions are considered the classic signs of a PD development. The 
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developments of resting tremors, bradykinesia, rigidity, or postural imbalance are the 
primary signs used to diagnose PD in patients. Further, the physician will also observe 
the severity of your response to drugs used to treat PD as a diagnostic method. Since the 
development of these motor control problems is indicative of significant loss to the 
dopaminergic neurons in the SNpc patients whom are diagnosed are later in the stages of 
PD progression[4]. This is a common scenario since there aren’t any diagnostic lab tests 
for PD. 
The current approved treatments for PD do not inhibit the mechanism in which 
PD causes its pathological effects. This is greatly due to the limited amount of knowledge 
of PD etiology. Most treatments for PD attempt to restore the proper levels of the 
neurotransmitter dopamine by increasing dopamine levels. L-dopa is commonly given to 
patients diagnosed with PD. L-dopa is the precursor to dopamine. Dopamine is unable to 
cross the blood brain barrier (BBB) and enter the brain cavity. L-dopa is able to cross the 
BBB and enter the brain cavity. Once L-dopa enters the brain cavity it is metabolized to 
produce dopamine. The effectiveness of this treatment decreases overtime and patients 
symptoms will continue to worsen after prolonged use[23, 24]. Other drug therapies 
inhibit the degradation of dopamine and reduce the effects of acetylcholine, a 
neurotransmitter that can cause a drop in dopamine levels[25]. Deep brain stimulation 
(DBS) has recently been implemented as a procedure that can provide dramatic 
improvements in many patients’ symptoms. In this procedure, a wire is placed in a 
specific location deep within the brain. An electric current is then induced in the wire 
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thus stimulating the brain. The mechanism in which DBS works through is not 
completely understood[26]. 
Risk factors for developing PD have been extensively researched. These studies 
have attempted to identify the non-genetic and genetic risk factors for PD. The discovery 
of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and its damaging effects on the 
dopaminergic neurons in the SNpc led to the hypothesis that exposure environmental 
toxins may be a risk factor of PD[27]. Evidence consistently points towards a positive 
association between presticide exposure and PD risk[28]. Multiple epidemiological 
studies have shown a reduced risk of PD among cigarette smokers[29]. The biological 
basis that may underlie this association is still poorly understood. Caffeine consumption 
was shown to significantly decrease PD risk according to a meta-analysis based on eight 
case-control studies and five cohort studies. Caffeine is an inhibitor of the adenosine A2 
receptor and improves motor deficits in a mouse model of PD[30]. Studies have also 
shown that higher intake of polyunsaturated fatty acids significantly reduce PD risk[31]. 
Genetic risk factors for PD have been extensively researched since the discovery 
of monogenetic mutations that have been shown to correlate with higher risk for PD. 
These mutations are considered either inheritable or idiopathic (sporadic). The former 
mutations clearly operate under Mendelian inheritance. These forms of mutations are 
estimated to cause about 10% of PD cases. Mutations in the gene for the protein α-syn, 
and other proteins that are involved in cellular protection against oxidative stress, 
mitochondrial dysfunction are among the mutations known. The sporadic mutations do 
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not operate under Mendelian inheritance[32]. They are thought to result from complex 
interactions between environmental and genetic factors. Genes associated with dopamine 
metabolism, mitochondrial metabolism, detoxification, other neurodegenerative diseases, 
and familial PD are commonly studied candidates for mutation that cause sporadic PD 
development in patients. 
Synucleopathies  
 Pathology 
James Parkinson first described a neurodegenerative disease condition he called 
“shaking palsy” in 1817. He described individuals exhibiting tremors, rigidity, and 
considerable debilitations in motor control[33]. PD pathology is defined by a loss of 
dopamine producing neuronal cells in the SNpc and the presence of LB/LN. These 
dopaminergic neurons of the SNpc indirectly play a critical role in fine motor control and 
learned responses to stimuli. Dopamine modulates neuronal synaptic activity which is 
needed for fine and gross motor control. Low dopamine levels in the brain, caused by the 
dopaminergic neuron death in PD, result in stiffness with reduced and slowed 
movement[3, 34]. 
The LB was first described by Friederich Lewy in 1912 in substantia innominata 
samples from individuals that exhibited Parkinsonism-like symptom [5]. Its biochemical 
composition remained unknown until 1997. Soon after the discovery of a point mutation 
in the α-syn  gene as a cause for inheritable PD, α-syn  was found to be the major 
component of LB/LN in LB/LN forming synucleopathies such as PD and dementia with 
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lewy bodies (DLB)[6-8]. The filamentous glial and neuronal inclusions of multiple 
system atrophy (MSA) have also been found to be made of α-syn [35].  
 
α-syn uclein 
The first synuclein nucleotide and amino acid sequences were reported by 
Maroteaux et al. in 1988. The protein received its name due to its localization in the 
presynaptic nerve terminals and portions of the nuclear envelope[36]. Following studies 
have failed to confirm a nuclear localization. Two other homologues of this original 
synuclein have been discovered subsequently[36-38]. These synucleins have thusly been 
named α-syn , Β synuclein, and gamma synuclein. Β synuclein and Gamma synuclein 
have not shown any correlation with neurodegenerative disease to date.  
α-syn  is an amphipathic protein that has little secondary structure. This structure 
allows for a high level of heat-stability[39]. Structural research indicates that the 
intrinsically unstructured α-syn  forms an alpha helical confirmation at the N-terminal in 
the presence of cellular membranes. Unique to α-syn  is a central hydrophobic region 
known as the non-B-amyloid component (NAC) [39-41](Fig 3). Studies pertaining to 
Alzheimer’s disease indicate this region is essential for α-syn  aggregation. Deletion of 
this region has confirmed the role of the NAC in following studies. α-syn  can bind lipid 
membranes, and selectively inhibits phosopholipase D2. Phosopholipase D2 localizes to 
the plasma membrane where it plays a possible role in signal-induced cytoskeletal 
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regulation and endocytosis[42-45]. These observations lead many to believe α-syn  may 
have a role in regulating vesicular transport processes. 
 
Figure 3. Diagram of Alpha Synuclein. α-syn contains a highly conserved amphipathic 
region that forms an alpha helical structure in the presence of a lipid membrane (1-60). 
Α-syn also has a hydrophobic non-B-amyloid component (NAC) that is unique to α-syn 
and facilitates aggregation (61-95). Α-syn also has an acidic C-terminal. 
 
Pathological Alpha Synuclein 
In 1995,  Polymeropoulos et al. established a genetic link between L-Dopa 
responsive parkinsonism with Lewy body formation in a large Italian family and 
chromosome 4q21-23. Deletion of these genes proved to cause debilitating mental 
disfunction and development. In 1997, further investigation discovered a point mutation 
in the α-syn  gene in this family and three greek families that shared a common founder 
with the Italian family. In this A53T α-syn  mutation alanine (A) residue 53 is changed to 
threonine (T)[6]. The relevance of α-syn  within PD development was controversial since 
many rodents and zebra finch carry this mutation. This was later settled after the 
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discovery of another point mutation in the α-syn  gene in a German family with 
inheritable PD. In this A30P α-syn  mutation A residue 30 is changed to Proline (P)[46]. 
Since residue 30 is A in all species examined the scientific community agreed on the 
relevance of α-syn  in PD development. Soon after, it was discovered that α-syn  was the 
major component of LB/LN[6-8].  In 2003, Zarranz et al. reported the discovery of the 
third major point mutation in α-syn  in a Spanish family that suffered from autosomal 
dominant parkinsonism, dementia and visual hallucinations of varying severity. In this 
E46K mutation glutamic acid (E) residue 46 is changed to lysine (K). Mice expressing 
these mutant α-syn  develop neurological symptoms similar to those of PD[47]. 
Due to the abundance of α-syn  aggregation in the pathology of Parkinson’s 
disease a number of studies have investigated the amino acids of α-syn  that are critical to 
aggregation in vitro. The central hydrophobic region of α-syn  the NAC was found to be 
essential for α-syn  aggregation. The deletion of residues within the NAC region 
prevented α-syn  aggregation in vitro[40, 41]. In a transgenic Drosophila model with this 
α-syn  construct, there was no evidence of large aggregates or oligomeric species of α-
syn  in these animals and no loss of tyrosine hydroxylase-positive neurons. Transgenic 
Drosophila models with increased α-syn  aggregation exhibited increased neurotoxicity 
and loss of tyrosine hydroxylase positive neurons[48, 49].  
The animal models of PD that have been developed were either neurotoxin 
induced or through the development of a transgenic animal. These models don’t fully 
recapitualate the dopminergic neuron degeneration, motor deficits, and the LB/LN 
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accumulations found in PD pathology[50, 51]. In 2012, Luk et al. reported the initiation 
of Parkinson-like neurodegeneration in non-transgenic mice given intracranial 
inoculations with synthetic α-syn  fibrils. The fibrils were shown to seed aggregation of 
endogenous wt α-syn , transmit pathological α-syn  to other healthy cells, causes death 
of dopaminergic neurons and cause motor deficits in mouse model[10]. 
Reactive Oxygen Species (ROS) 
 In both sporadic and genetic PD, oxidative stress is thought to be the underlying 
mechanism that leads to cell dysfunction and death. The SNpc of PD patients have shown 
evidence of increased ROS production and decreased antioxidant activity[12-14]. 
Tyrosine hydroxylase is a known ROS-generating enzyme. This causes greater 
susceptibility to cellular damage from oxidative stress in dopaminergic neurons. 
Additionally nigral dopaminergic neurons contain iron, which catalyzes the Fenton 
reaction and contributes to further oxidative stress. Since the dopaminergic neurons are 
highly sensitive to ROS, moderate oxidative stress can result in cell death[13]. 
Dopamine is normally packaged within cytoplasmic vesicles. When the level of 
cytosolic dopamine becomes excessive it is oxidized into Dopamine Quinone due to 
ROS. Dopamine Quinone has been shown to covalently modify proteins whose 
dysfunction has been linked to PD pathophysiology. Α-syn  is one of the particular 
proteins that are modified by Dopamine Quinone. This modification of α-syn  promotes 
the protofibril formation of α-syn . This protofibril form of α-syn  is thought to be 
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pathogenic. Dopamine Quinone also causes mitochondrial dysfunction, as well as the 
inactivation of DA transporters and tyrosine hydroxylase[52, 53]. 
Multiple mutations in genes of mitochondrial proteins were discovered in the 
familial forms of PD[32]. Mitochondrial dysfunction is a common cause of dramatic 
increases in ROS production in multiple cell types. Neurons utilize mitochondrial aerobic 
respiration for ATP production. Hydrogen peroxide and super oxide radicals are 
byproducts formed during oxidative phosphorylation in the mitochondria. The increase in 
ROS production due to mitochondrial dysfunction can cause oxidative stress which can 
cause peroxidation of the mitochondria-specific lipid cardiolipin. This results in the 
release of cytochrome c into the cytosol, which initiates the apoptosis pathway. MPTP 
was discovered to cause Parkinson’s Disease –like symptoms in individuals by causing 
mitochondria dysfunction in neurons of the SNpc. It achieves this by causing damage to 
Complex I of the electron transport chain. This causes leakage of electrons, which thus 
causes ROS generation. Α-syn  has been shown to interact with mitochondrial 
membranes and inhibit Complex I[15] (Fig 4). 
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Figure 4. MPTP damages Complex I of the electron transport chain. MPTP mimics the 
effects of Parkinson’s Disease by damaging Complex I of the electron transport chain. This 
causes a leakage of electrons that in turn leads to increased ROS production. 
 
Loss of neuronal cells due to neuroinflammation is common in organisms with 
PD. The neuroinflammatory response is controlled by microglia. Microglia are innate 
immune cells located in the central nervous system. They are the main immune 
responsive cells in the central nervous system. Microglia are considered to be “resting” 
when they are not “activated” by chemical stimulants generated due to brain damage 
and/or the presence of an antigen. Once activated the microglia release free radicals such 
as nitric oxide and superoxide while functioning as an innate responsive cell. These free 
radicals contribute to the oxidative stress of the microenvironment. The SNpc of sporadic 
and familial PD patients have increased levels of activated microglia[54]. It has been 
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shown that the addition of aggregated α-syn  to a primary mesencephalic neuron-glia 
culture causes activation of microglia and dopaminergic neurodegeneration. This 
cytotoxicity does not occur when microglia are absent from the culture[55]. Neuron 
derived α-syn  stimulates astrocytes to produce inflammatory modulators which augment 
microglial chemotaxis, activation, and proliferation[56]. Currently, there is no therapy 
clinically available that delays the neurodegenerative process. 
Ruptured Vesicles 
Evidence indicates that pathological α-syn  has the ability to be transferred from 
an infected neuronal cell to a healthy neuronal cell[57-60]. It has been hypothesized that 
the pathological forms of α-syn  enter the cells via endocytosis. This theory called into 
question the method in which α-syn  escapes the vesicle in order to enter the cytosol. 
Previous work with Adenovirus Type 5 has shown that the rupturing of lysosomes in 
cells caused by adenovirus infection leads to Cathepsin B- Dependent Mitochondrial 
Stress and the production of ROS[15]. Since similar physiological signs are present in the 
cells of PD patients, our lab suggested that α-syn  enter the cell via endocytosis and 
ruptures from lysosomes. These hypotheses were later confirmed through 
experimentation.  α-syn  aggregates were shown to localize to areas of vesicle rupture in 
vitro (Fig 2). These ruptured vesicles were shown to be positive for lysosomal associated 
membrane protein-2 (LAMP2). This indicates that the vast majority of vesicles ruptured 
by α-syn  are lysosomes[16]. Previous studies of the α-syn  protein have shown that low 
pH environments cause α-syn  to undergo a conformational change[61]. Therefore, the 
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low pH environment of the lysosome may cause a conformation change in the α-syn  
which allows it to rupture the vesicle and escape into the cytoplasm. The rupture of 
lysosomes has been associated with an increase in cellular ROS in cells due to the release 
of activated cathepsins contained within the lysosome. Furthermore, α-syn  induces a 
cathepsin B dependent increase in ROS in infected cells[16].  
Galectin 3 
Galectins are a family of evolutionary conserved animal lectins that bind β-
galactosides. They are found ubiquitously in mammals, invertebrates and fungi[62]. 
Galectins have considerable immunoregulatory activities including regulation of immune 
homeostasis[63]. All galectins exhibit sequence homology in the carbohydrate 
recognition domain (CRD) but they have different affinities for different saccharide 
ligands[64]. Gal3 (Gal3) is a structurally unique member of the galectin family and 
exhibits both extracellular and intracellular functions. It is important to note that Gal3 
doesn’t posses a secretion signal peptide that would direct transport through the classical 
endoplasmic reticulum-Golgi apparatus secretory pathway. Gal3 contains a single CRD 
and an elongated N-terminus compared to other galectin members (Table 1). This 
elongated N-terminus plays a role in protein oligomerization and is believed to participate 
in the interaction with other intercellular proteins. Therefore Gal3 can interact with both 
carbohydrates and proteins[65, 66]. At low concentrations, Gal3 is a monomer that can 
potentially form oligomers upon binding to multivalent saccharides. Gal3 has the ability 
to crosslink cell surface receptors, thus forming a cluster of ligands into a lipid raft micro-
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domains[67, 68]. Gal3 ability to bind cell surface receptor has been shown to affect 
multiple cellular processes including cell-cell adhesion, proliferation, differentiation, and 
cytokine secretion[69-72]. Additionally, Gal3 has both a pro- and anti- apoptotic 
activities determined by extracellular or intercellular location[73]. Gal3 is now known to 
be related the pathophysiology of multiple diseases, including cardiovascular disease, 
cancer, asthma, prion infection, rheumatoid arthritis and streptococcus pneumonia 
infections. In vivo, an increase in the extracellular concentration of Gal3 has been 
measured in the inflammatory setting in animal models. Gal3 levels are currently being 
used as an indicator of multiple types of infections and disease conditions in clinical 
medicine settings[74-76]. Gal3 was discovered to be regulated at the protein level in 
response to IL-1B, and at the mRNA level in response to advanced glycation end 
products casein[77]. These findings are consistent with the up regulation of Gal3 during 
innate immune activation. 
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Table 1. Galectin 3 has a unique structure compared to other members of the 
Galectin family. Gal3 is the only chimeric type member of the Galectin family. It 
contains one carbohydrate recognition domain and one dimer binding site. Gal3 has a 
uniquely elongated N-terminus. This elongated N-terminus is believed to give Gal3 
inflammatory regulatory capabilities. 
 
Multiple studies show that Gal3 has a critical role in the process of leukocyte 
trafficking, activation and cytokine release[78]. Gal3 was discovered to cause Calcium 
influx in monocytes. This calcium influx involves a pertussis toxin-sensitive pathway, 
which suggest a G protein-coupled receptor could be a target receptor for Gal3[79]. In 
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vitro, Gal3 can cause superoxide release from monocytes and promote the uptake of 
apoptotic neurtrophils from monocyte derived macrophages[79-81]. The macrophages of 
mice deficient in Gal3 showed reduced phagocytosis apoptotic thymocytes in vitro 
compared to wild type mice. Phagocytic clearance of apoptotic thymocytes by peritoneal 
macrophages was attenuated in Gal3 deficient mice in vivo[74]. These studies suggest 
Gal3 is a pro-inflammatory protein. It is important to mention that recent studies 
pertaining to the role Gal3 plays in salmonella infection and asthma have suggested that 
Gal3 also acts as an anti-inflammatory protein[82, 83]. These results may not represent 
the effect of endogenous Gal3. A large number of in vivo and in vitro studies suggest that 
Gal3 is pro-inflammatory. 
 Within the last 5 years Gal3 has been utilized as a marker of vacuole lysis by 
invasive pathogens. Multiple infectious agents, including Shigella bacteria, must evade 
the immune system while invading the host. Upon internalization into the host cell the 
bacteria lyses the phagosome before it is fused with a lysosome and escapes into the 
cytosol[84]. This process was poorly understood since there wasn’t a reliable marker for 
ruptured vesicles. Paz and company utilized the affinity that Gal3 has for the β-
galactosides sugars on the inner leaflet of the ruptured vesicles to identify ruptured 
vesicles. Once the bacteria lysed the vesicle the β-galactoside sugars were exposed to the 
cytosol and the cytosolic Gal3. By labeling the Gal3 after bacterial infection Paz and 
company were able to reliably identify ruptured vesicles which would have clusters of 
oligermerized Gal3 bound to their inner walls[17]. 
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Photoactivatable Green Flourescent Protein fused to Galectin 3 
The utilization of fluorescent proteins, such as green fluorescent protein (GFP), 
allows for non-invasive analysis of protein localization and dynamics in living cells[85]. 
This is achieved by producing a fusion protein with the fluorescent protein and a protein 
of interest. This fusion protein can then be expressed in a cell or organism and its 
movements can be tracked via fluorescent microscopy. Innovation developed using these 
fluorescent proteins include the production of photoactivatable fluorescent proteins 
(PFAP)[86]. One such protein created by utilizing GFP is photoactivatable GFP 
(PAGFP). When initially expressed PAGFP emits low intensity light. After exposure to 
approx. 400 nm wavelength light (UV light) the PAGFP will undergo irreversible 
photoconversion causing it to emit light with nearly 100 fold greater intensity (Fig 5). 
This photoconversion involves the decarboxylation of Glu222 followed by chromophore 
conversion from a neutral to anionic state[86]. PAFP’s introduce a new methodology of 
kinetic microscopy of living cells, which was traditionally associated with fluorescence 
recovery after photobleaching (FRAP)[87]. It is worth mentioning that some PAFPs 
undergo a reversible photoconversion process[88]. These photoactivatable proteins are 
also useful when overcoming hindrances to resolution that can develop that can develop 
when viewing tissue samples using fluorescent microscopy techniques, such as tissue 
autoflourescence [89, 90].  
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Figure 5. Photoactivatable green fluorescent protein increases its light intensity by nearly 
100 fold after activation with ≈400 nm light (UV light). The photoconversion of 
photoactivatable green fluorescent protein is an irreversible process. It is widely used in protein 
kinetics studies to track proteins in living models. Prior to exposure to UV light the PAGFP will 
emit a low level of fluorescent light. Following exposure PAGFP will increase its fluorescent 
light intensity by nearly 100 fold. 
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CHAPTER TWO 
EXPERIMENTAL METHODS 
Cell lines and reagents  
The human monocyte cell line THP-1 was obtained from the American Type Culture 
Collection (ATCC). ATP and phorbol-12-myristate-13-acetate (PMA) were purchased 
from Sigma-Aldrich. PMA was used to differentiate Thp-1 monocytes. The THP-1 cells 
were maintained in Roswell Park Memorial Institute (RPMI) 1640 media, supplemented 
with 10% fetal bovine serum (FBS), 100 IU/ml penicillin, 1mg/ml streptomycin, 1mM 
sodium pyruvate and 2 mM glutamine. The human neuroblastoma cell line, SH-SY5Y 
was obtained from the American Type Culture Collection (ATCC). SH-SY5Y cells were 
maintained in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% 
(FBS)(Hyclone) and 100 IU/mL penicillin, 1mg/mL streptomycin and 10 µg/mL 
ciprofloxacin. Cells were maintained in a 37°C incubator with 5% CO2. The mCherry-
gal3 plasmid was a generous gift from Dr. Christopher Wiethoff. Retroviral vectors and 
Lentiviral vectors were generated utilizing transfection of 293T cells with the packaging 
plasmids vesicular stomatitis virus glycoprotein (VSV-g), delta nrf and mCherrygal-3. 
Transfections were performed using polyethylenimine (PEI) (molecular weight, 25,000; 
Polysciences). Supernatants containing these recombinant retroviral 38 vectors were 
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collected 48 hours post-transfection and used to transduce SH-SY5Y and THP-1 cells. 
Positive transductants were selected with Geneticin/G418. 
Alpha Synuclein 
Full length α-syn were purchased (rPeptide) and the lyophilized protein was rehydrated in 
PBS with 100 mM NaCl immediately upon arrival to a concentration of 1 mg/ml and was 
aliquoted and stored at -80°C. In order to generate aggregates, alphα-syn uclein was 
incubated for 3 days at 37°C under constant agitation at 300 revolutions per minute (rpm) 
followed by storage at -80°C. Aggregates were added at a concentration of 3µg/ml per 
the protocol provided by Volpicelli-Daley[91].  
 
Western Blot 
Purified proteins were separated via sodium dodecyl sulfate polyacrylamide gel  
electrophoresis, (SDS-PAGE), proteins were transferred to nitrocellulose membranes and 
detected by incubation with the primary antibody. The monoclonal mouse anti-human 
Gal3 antibody from BD Pharmingen was purified from tissue culture supernatant or 
ascites by affinity chromatography. Secondary antibody conjugated to HRP (Thermo 
Scientific) was used where necessary, and antibody complexes were detected using 
SuperSignal West Femto chemiluminescent substrate (Thermo Scientific). 
Chemiluminescence was measured using a BioRad ChemiDoc XRS imaging system 
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(BioRad). Gal3 values were quantified using Imagj software to perform densitomitry 
analysis of the western blot bands. 
 
Animals and Surgery 
Young adult Sprague Dawley rats (Charles River Laboratories, Wilmington, MA) were 
housed two to a cage with ad libitum access to food and water during a 12 h light/dark 
cycle, according to the rules set by the Research Ethical Committee at Rush University 
Medical Center. Recombinant adeno associated virus serotype 6 vector 
encoding human mutant (A30P) α-syn gene (rAAV6-h-A30P) were prepared and titered 
as described previously (Towne et al., 2008). Under halothane anesthesia, 2 μl of the 
vector suspension was injected stereotaxically into the right nigral region at 5.3 mm 
posterior and 2.3 mm lateral to bregma, 7.7 mm ventral to dura. The needle was kept in 
place for an additional 5 min before slowly being withdrawn. At 6 weeks after injection, 
animals (rAAV6-h-A30P, n= 10) were perfused through the ascending aorta with 
physiological saline, followed by 4% ice-cold paraformaldehyde. The brains were post-
fixed in the same solution for 2 h, transferred to10%, 20%, 30% sucrose, and sectioned 
on a freezing microtome at 40 μm in the coronal plane. All sections were collected and 
stored in order in a cryoprotectant solution before processing. All animal experiments had 
prior approval from the Institutional Animal Care and Use Committee at Rush University 
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Immunofluorescence Microscopy  
For in vitro experiments cells were allowed to adhere to Fibronectin (Sigma-Aldrich) 
treated glass coverslips and fixed with 3.7% formaldehyde (Polysciences) in 0.1 M 
piperazine-N, N'bis(2-ethanesulfonic acid) PIPES buffer at pH 6.8 for 15 min.  
For experiments utilizing rat brain tissue slides, primary antibodies to Gal3 and α-syn  
were used in their preparation. The monoclonal mouse anti-human Gal3 antibody from 
BD Pharmingen was purified from tissue culture supernatant or ascites by affinity 
chromatography.  
Primary antibodies were secondarily labeled with fluorophore-conjugated mouse anti-
human antibodies (Jackson ImmunoResearch). Images were collected with a DeltaVision 
microscope (Applied Precision) equipped with a digital camera (CoolSNAP HQ; 
photometrics), using a 1.4 numerical aperture (NA) 100X objective lens, and were 
deconvolved with SoftWoRx deconvolution software (Applied Precision). Structured 
Illumination images were collected on an OMX microscope (Applied Precision) and 
deconvolved and reconstructed using SoftWoRx software (Applied Precision). Tiff 
images and 3-dimensional reconstructions were generated using Imaris software 
(Bitplane).  
Image Analysis  
Deconvolved images were analyzed for colocalization of PAGFP Galectin-3 (Gal-3) with 
mCherry Galecint 3 by use of the Surpass Mode of the Imaris software package 
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(Bitplane).  
Statistical Analysis 
Results are presented as mean + standard error of the mean. Two-sample t-test was used 
to compare between different experimental groups. All statistical analyses were 
performed using InStat 3.0 (GraphPad Software). p<0.05 was considered statistically 
significant. 
 
Densitometry Analysis 
Western blots bands were analyzed utilizing ImageJ software. Control levels were 
normalized to a value of 100. Variable band values are expressed in comparison to the 
normalized control values of 100. Adjustments to Gal3 band values were made in 
proportion to the differences in their corresponding actin band values compared to the 
actin bands of the control samples.  
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CHAPTER THREE 
RESULTS 
Colocalization of Galectin 3 and α-syn  observed In vivo  
Gal3 is a lectin protein which binds the β-galactosides on the outer leaflet of the cell 
membrane and on the inner leaflet of the cellular vesicles. Once a vesicle is ruptured 
the Gal3 are able to enter the vesicle and bind the β-galactosides on its inner leaflet. 
The colocalization of Galectin3 and α-syn  at the site of ruptured lysosomes has been 
used to identify part of α-syn ’s pathway of infection. These in vitro data indicate that 
α-syn  enters the cell through endocytosis and then ruptures from the lysosome in 
order to enter the cytosol. In order to visualize this colocalization in vivo, histology 
slides were prepared using the brain tissue of rats that were treated with Adeno-
Associated-Virus (AAV) vector expressing the pathological α-syn  mutant A30P. 
These tissue samples were then stained with fluorescent anti-bodies to Gal3 and α-syn 
. The histology slides were examined under a fluorescent microscope. Visualization 
of α-syn  was clear, distinguishable, and isolated within the Cy5 channel. Contrarily, 
we were unable to isolate Gal3 in the FitC channel due to bleed through from tissue 
autofluorescence. This tissue autofluorescence hindered us from having clear 
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resolution of the Gal3. Thus, we weren’t able to visualize with certainty the 
colocalization of Gal3 and α-syn  in vivo.  
Galectin 3 levels increase in rat brain tissue when exposed to pathological alpha 
synuclein mutant (A30P) 
Increases in Gal3 levels have also been well documented during multiple pathogenic 
infections including streptococcus pneumonia and prion infection. We therefore wanted 
to determine whether Gal3 levels increased in vivo when a rat brain is exposed to a 
pathological mutant of the protein α-syn . Utilizing an A30P α-syn  expressing AAV 
vector and fluorescent antibodies to A30P α-syn  and Gal3 we were able to visualize and 
quantify differences in Gal3 levels during infection with pathological α-syn  in the rat 
brain (Figure 6A). We utilized rat brain tissue that was injected with AAV vector that 
wasn’t expressing the A30P α-syn  protein as our control group. The level of fluorescent 
intensity was indicative of the protein expression levels. Upon evaluation of multiple 
brain sections, we found that the levels of Gal3 had significantly increased in the brain of 
rats injected with the AAV vector expressing A30P α-syn  compared to the levels in the 
control rat brains (Figure 6B).  
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Figure 6. Galectin 3 levels in Rat Brain tissue treated with AAV expressing 
pathological alpha synuclein (A30P). Rat brain tissue sections from rats receiving right 
nigral brain injections of AAV expressing pathological α-syn  were stained with with 
fluorescently labeled antibodies to Gal3 (Green) and α-syn  (Red)(A). Gal3 levels in rat 
brain tissue tissue treated with AAV expressing pathological α-syn  had significantly 
higher Gal3 levels (B). Two-sample t-test, *p < 0.005, n = 5 rat brains with 68 brain 
regions analyzed.   
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Galectin 3 levels increase in neuronal cell line (Sy5y) during treatment with 
pathological alpha synuclein aggregates 
The brain is composed of multiple cell types. Two cell types which contribute greatly 
to the composition of the brain are the Neurons and Glial Cells. The increase in the levels 
of Gal3 in rat brain tissue following midbrain injection with virus vector expressing 
A30P α-syn  beckoned us to determine which cell type was responsible for this increase. 
We utilized Sy5y neuroblastoma cells as our neuronal cell line. The Sy5y cells were 
treated with pathological α-syn  aggregates and harvested at 24, and 48 hour time points.  
Gal3 levels were then determined qualitatively by western blot analysis (Figure 7A) and 
quantitatively by densitometry analysis (Figure 7B).  This allowed us to determine 
whether neuronal cells contribute to the increase in Gal3 levels. We found that Sy5y 
neuroblastoma cells showed a ≈ 50% increase in intercellular levels of Gal3 after 48 
hours of treatment via western blot analysis. Though increases in Gal3 levels were 
observed, the basal levels of Gal3 in Sy5y cells were considerably low. 
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Figure 7. Galectin 3 levels increase after treatment with alpha synuclein oligomers 
in Sy5y cells. Gal3 levels in SY5Y cells increase by approx. 50% after  48 hours of 
treatment with α-syn  oligomers (B). Cells were harvested at 24 hr and 48 hr time points. 
Gal3 levels were analyzed by western blot and quantified using Image J software and 
were normalized to control values (A). Control values normalized to 100.  
 
 
Galectin 3 levels increase in immune cell line (differentiated THP-1 monocytes) 
during treatment with pathological alpha synuclein aggregates 
With the discovery that our neuronal cell line has low basal levels of Gal3 we then 
wanted to analyze the change in the levels of Gal3 in glial cells after treatment with 
pathological aggregates of α-syn . Since microglia have been shown to be activated 
Gal3 
Actin 
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during PD progression we wanted to use them as our glial cell model. Differentiated Thp-
1 monocytes (macrophages) are known to produce large amounts of Gal3 and are widely 
utilized in studies of microglia. We utilized differentiated Thp-1 monocytes that were 
differentiated in macrophages as our representative glial cell line. Differentiated Thp-1 
macrophages are widely accepted as a representative cell line of microglial during 
experimentation. Differentiated Thp-1 cells were treated with pathological α-syn  
aggregates and harvested at 24, and 48 hour time points.  Gal3 levels were then 
determined qualitatively by western blot analysis and quantitatively by densitometry 
analysis (Figure 8A).  This allowed us to determine whether the glial cells are more 
likely to be the major contributors to the increase in Gal3 levels than neuronal cell types. 
We found that the differentiated Thp-1 monocytes showed a nearly 100 percent increase 
in intercellular levels of Gal3 after 48 hours of treatment (Figure 8B). The basal levels of 
Gal3 were comparably higher than that of our neuronal cell line making a 100 percent 
increase in Gal3 levels substantial. 
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Figure 8. Galectin 3 levels increase after treatment with alpha synuclein oligomers. 
Gal3 levels in THP-1 cells increase by approx 50% after 48 hours of treatments with α-
syn  oligomers (A). Cells were harvested at 24 hr and 48 hr time points. Gal3 levels were 
analyzed by western blot and quantified using Image J software and were normalized to 
control values (B). THP-1 data is representative of three independent experiments. 
Control values normalized to 100. 
 
 
 
PA-GFP Gal 3 CRD has similar binding properties to fully expressed Galectin 3 
In our attempt to use a green fluorescent protein labeled Gal3 (GFP-Gal3) to label 
ruptured vesicles in vivo, we were unable to resolve GFP-Gal3 puncta due to tissue 
Gal3 
Actin 
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autoflourescence. We have since utilized the photoactivatable fluorescent protein (PAFP) 
,phothoactivatable green flourescent protein (PAGFP) , in order to correctly resolve the 
Gal3 in the presence of tissue autoflourescents. This would be done by comparing the 
pre- and post- activation photos of the tissue sample and determining which source of 
light is being emitted by the PAGFP-GAL3. In order to utilize Gal3 as a marker of 
ruptured vesicles in our in vivo studies we want to express the PAGFP-Gal3 protein in 
the CNS of a transgenic mouse. Since Gal3 is known to function as an inflammatory 
regulator protein, we want to eliminate its inflammatory mediating function before 
expressing it in the CNS of a transgenic mouse. We accomplished this by expressing only 
the CRD region of Gal3. This would allow the fusion protein to have the same binding 
characteristics as the fully expressed Gal3 while alleviating the potential complications 
caused by its inflammatory effects.  Western blot analysis of the PAGFP-Gal3 CRD 
(PAGFP-CRD) confirms that the fusion protein is properly expressed at ≈36 kD 
(expected size at 35 kD) (Figure 9B). The PAGFP-CRD is able to be activated through 
exposure to ≈400 nm light (Ultra violet light) and undergo photoconversion in vitro thus 
causing a nearly ten-fold increase in light intensity emission (Figure 9A). Finally, by 
expressing both fully expressed cherry Gal3 and PAGFP-CRD in the same cell we were 
able to observe similarities in their binding properties. The data shows that PAGFP-CRD 
exhibits identical binding properties to fully express cherry Gal3(chGal3) (Figure 9C).  
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Fig 9. PAGFP labelled Galectin 3 CRD exhibits binding properties similar to 
Galectin 3.  Gal3 CRD binds to β-galactosides in a similar manner as fully expressed 
Gal3(C). The antibodies used to label Gal3 CRD and PAGFP appear at the same level 
indicating the fusion protein is being expressed intact (B). The PAGFP fused to the 
Gal3/CRD emits higher intensity light once activated (A). 
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CHAPTER FOUR 
DISCUSSION 
The previous results were gathered while attempting to utilize Gal3 as a marker of 
ruptured vesicles in vivo. The progress gained in this study will allow us to test the 
hypothesis that pathological forms of α-syn  including mutants and oligomers are able to 
rupture lysosomes in vivo. This hypothesis was developed using previous work which 
showed that α-syn  aggregates have the ability to rupture lysosomes in vitro[16]. The 
affinity Gal3 has for the Β Galactoside sugars on the inner leaflet of 
lysosomes/endosomes has been utilized as a tool for determining pathogen etiology. 
Multiple pathogens enter the host cell during infection. It is necessary for these pathogens 
to evade the host immune system in order to survive. This is accomplished by the 
utilization of multiple evasion techniques and mechanism. One known evasion method 
includes endocytosis of the pathogen by the host cell followed by pathogenic vesicle 
escape into the cytosol. During the pathogens escape the vesicle is ruptured and the 
cytosol is able to access the internal space of the vesicle. This allows Gal3 proteins to 
enter the vesicle and bind its’ receptor[17]. While attempting to use Gal3 as a marker of 
ruptured vesicles in rat brain tissue that had been exposed to the pathogenic α-syn  mutant 
A30P we were unable to gain effective resolution of Gal3. This failure was due to the 
abundance of tissue autofluorescence. The visualization of the co-localization of the α-
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syn  mutant protein and the Gal3 protein is a critical part to the experiment. Since we 
were unable accomplish this we had to modify our approach in order to gain enough 
resolution of the Gal3 protein. Though we failed to visualize co-localization of the two 
proteins, we were able to quantify the levels of Gal3 in A30P treated tissue by use of 
fluorescent microscopy. This quantification showed that Gal3 levels were significantly 
increased in tissue samples that were exposed to the pathological A30P α-syn  protein. It 
is well documented that Gal3 levels are increased in multiple disease states including 
cardiovascular disease, cancer, asthma, prion infection, rheumatoid arthritis and 
streptococcus pneumonia infections[74-76]. Increases in Gal3 levels pertaining to 
synucleiopathies such as parkinson’s disease has yet to be documented. Previous work 
has indicated that Gal3 is involved in innate immune activation and is regulated at the 
protein level by IL-1B, an inflammatory cytokine. This observation correlates with 
previous work which indicated an increase in IL-1B levels in the substantia nigra of PD 
patients[92, 93]. It also correlates with data that shows α-syn  aggregates are able to cause 
caspase 1 activation in vitro, thus causing the release of IL-1B[16].  
Gal3 is a useful marker of ruptured vesicles largely due to its diffuse distribution in a 
cells cytoplasm. In the presence of ruptured vesicles these diffuse proteins aggregate on 
the inner leaflet of these ruptured vesicles. These aggregates amplify the signal of the 
fluorescently labeled Gal3 distinguishably from that of the diffuse protein. Therefore, a 
strong contrast between the signal intensity of the diffuse Gal3 from the aggregated Gal3 
proteins is critical to the efficacy of Gal3 as a marker of ruptured vesicles. Consequently, 
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an increase in the concentration of diffuse cytosolic Gal3 would diminish the 
effectiveness of Gal3 as a marker of ruptured vesicles.  
Neurons and Glial cells are two major types of cells present in the composition of the 
CNS. Since we are ultimately interested in utilizing Gal3 as a marker of ruptured vesicles 
in neuronal cell lines we want to determine whether neuronal cells contribute to the 
increase in Gal3 concentrations and, if so, how large is the relative contribution. We 
decided to utilize differentiated THP-1 cells as our representative Glial cell line and SH-
Sy5y human neuroblastoma cells as our neuronal cell line. We treated SH-Sy5y human 
neuroblastoma cells and differentiated THP-1 human monocyte cells with α-syn  
oligomers for up to 48 hours. Western blot analysis showed increases in Gal3 levels in 
both cell types. The most significant increases were observed at 48 hours. Though the 
Sy5y neuroblastoma cells did show a nearly 50% increase in Gal3 levels their basal Gal3 
levels were significantly lower than those of the differentiated human monocyte THP-1 
cells. The THP-1 cells exhibited a nearly 100% increase in Gal3 levels following 48 
hours of treatment. These results lead us to believe that the neurons are not the major 
contributor of Gal3 production in the CNS during pathological α-syn  infection.  
It is important to note that this α-syn  induced increase in Gal3 levels eliminates 
the use of endogenous Gal3 as a useful marker of ruptured vesicles in vivo. The newly 
expressed Gal3 is released into the cytosol of the infected cell. If the concentration of 
Gal3 in the cytosol increases then the contrast between diffuse cytosolic Gal3 and the 
aggregated vesicular Gal3 will become less distinguishable. These protein dynamics also 
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renders the capability of our software to quantify and calculate fluorescent data 
inadequate. The increase in overall Gal3 levels in the cell would cause a considerable 
amount of variability in the experiment data. This variability would thus cause imprecise 
analysis to be produced.   
In order to utilize Gal3 as a marker of ruptured vesicles in vivo we would have to 
overcome the loss of resolution due to tissue autofluorescence as well as the increased 
cytosolic Gal3 concentrations due to pathological α-syn  treatments. We elected to 
accomplish this by fusing Gal3 to the fluorescent protein photoactivatable green 
fluorescent protein (PAGFP). The fusion protein exhibits expression levels that are not 
affected due to α-syn  pathology. Examination of the PAGFP-Gal3 protein indicates that 
it has the same binding property of endogenous Gal3. Analysis of the PAGFP-Gal3 
protein also confirmed its ability to be fluorescently activated when exposed to approx. 
400 nm light. This activation causes the fluorescence of the PAGFP to intensify 
approximately 100 fold. This change in light intensity allows us to differentiate Gal3 
oligomer fluorescence from the autofluoresence of tissue samples.  
In order to complete our in vivo studies we will be expressing the PAGFP-Gal3 in 
the cells of CNS of a transgenic mouse. Gal3 is known to be an inflammatory regulating 
protein[82]. This function is unique to the Gal3 within the Galectin family of proteins. 
The uniqueness of the structure of Gal3 is believed to give Gal3 this unique function.  
Increasing the expression of an inflammatory regulating protein in the CNS of a 
transgenic mouse can cause lower animal viability and even death. In order to alleviate 
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this concern, we expressed the homologous CRD region of the Gal3 protein fused to the 
PAGFP (PAGFP-CRD). This eliminates the unique structure of Gal3 as well as its’ 
unique inflammatory regulating function. Analysis of the PAGFP-CRD protein indicates 
that it has similar binding properties to Gal3. Analysis of the PAGFP-CRD protein also 
confirmed its ability to be fluorescently activated when exposed to approx. 400 nm light. 
 The PAGFP-CRD will be expressed in the CNS of a transgenic mouse. The 
transgenic mouse will be treated with pseudovirus vector expressing a pathological 
mutant of α-syn . The brains will then be harvested and prepared to be analyzed by 
fluorescent microscopy based on the methods developed by the Kordower lab. We 
believe this analysis will provide evidence that the pathological α-syn  enters the cell 
through endocytosis and ruptures from the vesicle in order to enter the cytosol.  
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